Item type |
文献 / Documents(1) |
公開日 |
2022-06-06 |
アクセス権 |
|
|
アクセス権 |
open access |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1038/s41440-021-00752-9 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1038/s41440-021-00752-9 |
出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
タイトル |
|
|
タイトル |
Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia : a sub analysis of the PRIZE Study |
|
言語 |
en |
著者 |
楠瀬, 賢也
ヨシダ, ヒサコ
タナカ, アツシ
テラガワ, ヒロキ
アカサキ, ユウイチ
フクモト, ヨシヒロ
エグチ, カズオ
カミヤ, ハルオ
カリオ, カズオミ
山田, 博胤
佐田, 政隆
ノデ, コウイチ
|
抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Hyperuricemia is related to an increased risk of cardiovascular events from a meta-analysis and antihyperuricemia agents may influence to cardiac function. We evaluated the effect of febuxostat on echocardiographic parameters of diastolic function in patients with asymptomatic hyperuricemia as a prespecified endpoint in the subanalysis of the PRIZE study. Patients in the PRIZE study were assigned randomly to either add-on febuxostat treatment group or control group with only appropriate lifestyle modification. Of the 514 patients in the overall study, 65 patients (31 in the febuxostat group and 34 in the control group) who had complete follow-up echocardiographic data of the ratio of peak early diastolic transmitral flow velocity (E) to peak early diastolic mitral annular velocity (e′) at baseline and after 12 and 24 months were included. The primary endpoint was a comparison of the changes in the E/e′ between the two groups from baseline to 24 months. Interestingly, e′ was slightly decreased in the control group compared with in the febuxostat group (treatment p = 0.068, time, p = 0.337, treatment × Time, p = 0.217). As a result, there were significant increases in E/e′ (treatment p = 0.045, time, p = 0.177, treatment × time, p = 0.137) after 24 months in the control group compared with the febuxostat group. There was no significant difference in the serum levels of N-terminal-pro brain natriuretic peptide and high-sensitive troponin I between the two groups during the study period. In conclusions, additional febuxostat treatment in patients with asymptomatic hyperuricemia for 24 months might have a potential of preventable effects on the impaired diastolic dysfunction. |
|
言語 |
en |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
febuxostat |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hyperuricemia |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
echocardiography |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
diastolic function |
キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
NT-proBNP |
書誌情報 |
en : Hypertension Research
巻 45,
号 1,
p. 106-115,
発行日 2021-10-17
|
収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
09169636 |
収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13484214 |
収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA10847079 |
出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
出版者 |
|
|
出版者 |
The Japanese Society of Hypertension |
|
言語 |
en |
権利情報 |
|
|
言語 |
en |
|
権利情報 |
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
EID |
|
|
識別子 |
383571 |
|
識別子タイプ |
URI |
言語 |
|
|
言語 |
eng |